Motley Fool
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
➖
AI Sentiment
Neutral
4/10
- Home
- MIRM
as of 03-24-2026 2:39pm EST
$87.91
$1.47
-1.64%
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 5.4B | IPO Year: | 2019 |
| Target Price: | $114.67 | AVG Volume (30 days): | 763.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.47 | EPS Growth: | 74.59 |
| 52 Week Low/High: | $36.88 - $109.28 | Next Earning Date: | 05-06-2026 |
| Revenue: | $19,138,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 26.22% | Revenue Growth (next year): | 21.77% |
| P/E Ratio: | -187.53 | Index: | N/A |
| Free Cash Flow: | 54.9M | FCF Growth: | +488.01% |
Stock Insider Trading Activity of Mirum Pharmaceuticals Inc. (MIRM)
BJERKHOLT ERIC
Sell
CHIEF FINANCIAL OFFICER
MIRM Mar 16, 2026
Avg Cost/Share
$91.98
Shares
7,287
Total Value
$670,242.96
Owned After
49,788
SEC Form 4
Radovich Peter
Sell
PRESIDENT AND COO
MIRM Mar 16, 2026
Avg Cost/Share
$91.98
Shares
16,515
Total Value
$1,519,015.02
Owned After
40,272
SEC Form 4
Peetz Christopher
Sell
CHIEF EXECUTIVE OFFICER
MIRM Mar 16, 2026
Avg Cost/Share
$91.98
Shares
40,985
Total Value
$3,769,714.23
Owned After
194,309
SEC Form 4
Howe Jolanda
Sell
SVP, GLOBAL CONTROLLER
MIRM Mar 16, 2026
Avg Cost/Share
$91.98
Shares
4,732
Total Value
$435,239.42
Owned After
8,429
SEC Form 4
Quan Joanne
Sell
CHIEF MEDICAL OFFICER
MIRM Mar 16, 2026
Avg Cost/Share
$91.98
Shares
7,287
Total Value
$670,242.96
Owned After
18,864
SEC Form 4
Ramasastry Saira
Sell
Director
MIRM Mar 16, 2026
Avg Cost/Share
$90.76
Shares
2,000
Total Value
$181,520.00
Owned After
0
SEC Form 4
Ramasastry Saira
Sell
Director
MIRM Feb 13, 2026
Avg Cost/Share
$102.09
Shares
2,000
Total Value
$204,180.00
Owned After
0
SEC Form 4
Radovich Peter
Sell
PRESIDENT AND COO
MIRM Feb 2, 2026
Avg Cost/Share
$103.30
Shares
2,631
Total Value
$271,791.51
Owned After
40,272
SEC Form 4
Peetz Christopher
Sell
CHIEF EXECUTIVE OFFICER
MIRM Feb 2, 2026
Avg Cost/Share
$103.30
Shares
9,108
Total Value
$940,888.28
Owned After
194,309
SEC Form 4
Howe Jolanda
Sell
SVP, GLOBAL CONTROLLER
MIRM Feb 2, 2026
Avg Cost/Share
$103.30
Shares
968
Total Value
$99,997.79
Owned After
8,429
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| BJERKHOLT ERIC | MIRM | CHIEF FINANCIAL OFFICER | Mar 16, 2026 | Sell | $91.98 | 7,287 | $670,242.96 | 49,788 | |
| Radovich Peter | MIRM | PRESIDENT AND COO | Mar 16, 2026 | Sell | $91.98 | 16,515 | $1,519,015.02 | 40,272 | |
| Peetz Christopher | MIRM | CHIEF EXECUTIVE OFFICER | Mar 16, 2026 | Sell | $91.98 | 40,985 | $3,769,714.23 | 194,309 | |
| Howe Jolanda | MIRM | SVP, GLOBAL CONTROLLER | Mar 16, 2026 | Sell | $91.98 | 4,732 | $435,239.42 | 8,429 | |
| Quan Joanne | MIRM | CHIEF MEDICAL OFFICER | Mar 16, 2026 | Sell | $91.98 | 7,287 | $670,242.96 | 18,864 | |
| Ramasastry Saira | MIRM | Director | Mar 16, 2026 | Sell | $90.76 | 2,000 | $181,520.00 | 0 | |
| Ramasastry Saira | MIRM | Director | Feb 13, 2026 | Sell | $102.09 | 2,000 | $204,180.00 | 0 | |
| Radovich Peter | MIRM | PRESIDENT AND COO | Feb 2, 2026 | Sell | $103.30 | 2,631 | $271,791.51 | 40,272 | |
| Peetz Christopher | MIRM | CHIEF EXECUTIVE OFFICER | Feb 2, 2026 | Sell | $103.30 | 9,108 | $940,888.28 | 194,309 | |
| Howe Jolanda | MIRM | SVP, GLOBAL CONTROLLER | Feb 2, 2026 | Sell | $103.30 | 968 | $99,997.79 | 8,429 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 25, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 25, 2026 · 100% conf.
AI Prediction SELL
1D
+1.21%
$109.94
Act: -15.13%
5D
-3.70%
$104.60
Act: -14.34%
20D
-0.89%
$107.66
Price: $108.62 Prob +5D: 0% AUC: 1.000
0001759425-26-000010
mirm-20260225false000175942500017594252026-02-252026-02-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2026
Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-3898183-1281555 (State or Other Jurisdiction of Incorporation) (Commission File Number)(IRS Employer Identification No.)
989 East Hillsdale Boulevard Suite 300
Foster City, California 94404 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (650) 667-4085 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per shareMIRM
Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 25, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits.
Exhibit No. Description
99.1 Press Release dated February 25, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Mirum Pharmaceuticals, Inc.
Date: February 25, 2026 By:/s/ Christopher Peetz Christopher Peetz Chief Executive Officer
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
AI Prediction SELL
1D
+1.21%
$109.94
Act: -15.13%
5D
-3.70%
$104.60
Act: -14.34%
20D
-0.89%
$107.66
Price: $108.62 Prob +5D: 0% AUC: 1.000
0001759425-26-000004
mirm-20260112false000175942500017594252026-01-122026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026
Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-3898183-1281555 (State or Other Jurisdiction of Incorporation) (Commission File Number)(IRS Employer Identification No.)
989 East Hillsdale Boulevard Suite 300
Foster City, California 94404 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (650) 667-4085 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per shareMIRM
Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On January 12, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release announcing, among other things, the Company's preliminary unaudited net product sales for the fiscal year ended December 31, 2025, preliminary unaudited net product sales of LIVMARLI (maralixibat) and CHOLBAM and CTEXLI, and preliminary unaudited cash, cash equivalents and investments. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 7.01 Regulation FD Disclosure. On January 12, 2026, in connection with its participation in the J.P. Morgan Healthcare Conference, the Company posted a corporate slide presentation in the “Investors” portion of its website at www.mirumpharma.com. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2. The information in this Current Report on Form 8-K, including Exhibit 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits.
Exhibit No. Description
99.1 Press Release dated January 12, 2026
99.2 Investor Presentation dated January 12, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Mirum Pharmaceuticals, Inc.
Date: January 12, 2026By:/s/ Christopher Peetz Christopher Peetz Chief Executive Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 4, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 4, 2025
0001759425-25-000053
mirm-20251104false000175942500017594252025-11-042025-11-04
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025
Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware001-3898183-1281555 (State or Other Jurisdiction of Incorporation) (Commission File Number)(IRS Employer Identification No.)
989 East Hillsdale Boulevard Suite 300
Foster City, California 94404 (Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (650) 667-4085 N/A (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per shareMIRM
Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 4, 2025, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits.
Exhibit No. Description
99.1 Press Release dated November 4, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Mirum Pharmaceuticals, Inc.
Date: November 4, 2025 By:/s/ Christopher Peetz Christopher Peetz Chief Executive Officer
Latest Mirum Pharmaceuticals Inc. News
MIRM Breaking Stock News: Dive into MIRM Ticker-Specific Updates for Smart Investing
Motley Fool
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
📈
AI Sentiment
Highly Positive
8/10
Insider Monkey
Mirum Pharmaceuticals (MIRM) Completes Enrollment for Phase 3 EXPAND Study of LIVMARLI
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Mirum EXPAND Enrollment Milestone Highlights LIVMARLI Upside And Valuation Gap
📊
AI Sentiment
Positive
7/10
Zacks
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli
📈
AI Sentiment
Highly Positive
9/10
Compare MIRM vs Leading Stocks
See how MIRM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MIRM Mirum Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.